AngioDynamics (NASDAQ:ANGO) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.
ANGO has been the topic of several other research reports. Zacks Investment Research downgraded AngioDynamics from a “buy” rating to a “hold” rating in a report on Friday, January 26th. TheStreet cut AngioDynamics from a “b-” rating to a “c” rating in a research note on Tuesday, January 2nd. Finally, Craig Hallum cut AngioDynamics from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Six analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. AngioDynamics currently has a consensus rating of “Hold” and a consensus price target of $18.60.
Shares of AngioDynamics (ANGO) opened at $16.84 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.65 and a current ratio of 2.56. The stock has a market capitalization of $607.77, a PE ratio of -80.19, a price-to-earnings-growth ratio of 1.53 and a beta of 0.98. AngioDynamics has a twelve month low of $14.80 and a twelve month high of $18.85.
AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, January 4th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.16. The firm had revenue of $86.70 million for the quarter, compared to the consensus estimate of $88.15 million. AngioDynamics had a positive return on equity of 4.63% and a negative net margin of 2.27%. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.19 EPS. equities analysts expect that AngioDynamics will post 0.72 earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in AngioDynamics by 1.7% during the 4th quarter. BlackRock Inc. now owns 4,730,396 shares of the medical instruments supplier’s stock valued at $78,666,000 after acquiring an additional 76,859 shares in the last quarter. Vanguard Group Inc. grew its stake in AngioDynamics by 14.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,938,115 shares of the medical instruments supplier’s stock valued at $31,416,000 after acquiring an additional 243,825 shares in the last quarter. Janus Henderson Group PLC grew its stake in AngioDynamics by 49.4% during the 3rd quarter. Janus Henderson Group PLC now owns 1,439,873 shares of the medical instruments supplier’s stock valued at $24,607,000 after acquiring an additional 476,327 shares in the last quarter. Northern Trust Corp grew its stake in AngioDynamics by 14.9% during the 2nd quarter. Northern Trust Corp now owns 1,202,941 shares of the medical instruments supplier’s stock valued at $19,500,000 after acquiring an additional 155,951 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in AngioDynamics by 11.0% during the 4th quarter. Wells Fargo & Company MN now owns 1,138,161 shares of the medical instruments supplier’s stock valued at $18,928,000 after acquiring an additional 112,928 shares in the last quarter. 99.63% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/22/angiodynamics-ango-rating-increased-to-hold-at-bidaskclub.html.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.